Drug Trial Radar · NCT05397041
A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Jun 6, 2022
Primary completion
May 4, 2023
Study completion May 4, 2023
Sponsor
- Lead sponsor
- Bright Minds Biosciences Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed as a single centre, double blind, placebo controlled, randomized, SAD/FE/MAD, safety, tolerance and PK study of BMB-101 in healthy adult subjects. The study will be conducted as a 3-part study.
Conditions
- Healthy
Interventions
BMB-101Drug
Participants will receive one of several different oral doses of BMB-101 once or twice daily
PlaceboDrug
Matched Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment-emergent Adverse EventsTime frame: Baseline up to Follow Up/End of Treatment visit, an average of 8 months.
- Change in Columbia-Suicide Severity Rating Scale (C-SSRS) ResponseTime frame: Administered at each of the following visits in Part 3: Screening, Clinic Discharge, and Follow-up/Early Withdrawal.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.